Drug Profile
LY 3076226
Alternative Names: anti-FGFR3 Ab IMC-D11; LY3076226Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Bacterial toxins; Drug conjugates; Immunotoxins; Maytansinoids
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 28 Apr 2019 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease) in USA (IV)
- 29 Mar 2019 Pharmacodynamics data from a preclinical trial inCander presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)